Publications by authors named "Nicholas Paton"

Claim this Profile
C
Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.
Cissy Kityo, Ivan K Mambule, Joseph Musaazi, Simiso Sokhela, Henry Mugerwa, Nicholas I Paton

Nat Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial.
Nicholas I Paton, Christopher Cousins, Intan P Sari, Erlina Burhan, Nan-Kai Ng

Lancet Infect Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation for fungal pulmonary infections is essential in suspected tuberculosis relapse - Authors' reply.
Nicholas I Paton, Christopher Cousins, Ka Lip Chew

Lancet Infect Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process.
Chloe Orkin, Amy Paterson, Alexa Elias, Melanie Smuk, Kyle Ring, Nicholas Paton

Lancet HIV· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimised second-line regimens in the public health approach.
Nicholas I Paton

Lancet HIV· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PET-CT outcomes from a randomised controlled trial of rosuvastatin as an adjunct to standard tuberculosis treatment.
Gail B Cross, Intan P Sari, Sarah M Burkill, Chee Woei Yap, Han Nguyen, Nicholas I Paton

Nat Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
Cissy Kityo, Ivan K Mambule, Joseph Musaazi, Simiso Sokhela, Henry Mugerwa, Nicholas I Paton

Lancet Infect Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in the treatment of tuberculosis.
Ilaria Motta, Martin Boeree, Dumitru Chesov, Keertan Dheda, Gunar Günther, Nicholas I Paton

Clin Microbiol Infect· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial.
Nicholas I Paton, Meera Gurumurthy, Qingshu Lu, Francesca Leek, Philip Kwan

J Infect Dis· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Target regimen profiles for tuberculosis treatment.
Christian Lienhardt, Kelly E Dooley, Payam Nahid, Charles Wells, Theresa S Ryckman, Nicholas I Paton

Bull World Health Organ· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does PET-CT Have a Role in the Evaluation of Tuberculosis Treatment in Phase 2 Clinical Trials?
Gail B Cross, Jim O' Doherty, Christina C Chang, Anthony D Kelleher, Nicholas I Paton

J Infect Dis· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT).
Nicholas I Paton, Wolfgang Stöhr, Alejandro Arenas-Pinto, Amanda Clarke, Ian Williams

EClinicalMedicine· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral Neuropathy in Virologically Suppressed People Living with HIV: Evidence from the PIVOT Trial.
Anna L Schuldt, Henry Bern, Melanie Hart, Mark Gompels, Alan Winston, Nicholas I Paton

Viruses· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial.
Gail B Cross, Intan P Sari, Cissy Kityo, Qingshu Lu, Yogesh Pokharkar, Nicholas I Paton

Lancet Infect Dis· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Strategy for Rifampin-Susceptible Tuberculosis. Reply.
Nicholas I Paton, Christopher Cousins, Celina Suresh

N Engl J Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of sub-optimal HIV viral control on activated T cells.
Francesca I F Arrigoni, Moira Spyer, Patricia Hunter, Dagmar Alber, Cissy Kityo, Nicholas I Paton

AIDS· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Strategy for Rifampin-Susceptible Tuberculosis.
Nicholas I Paton, Christopher Cousins, Celina Suresh, Erlina Burhan, Ka Lip Chew

N Engl J Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
Nicholas I Paton, Joseph Musaazi, Cissy Kityo, Stephen Walimbwa, Anne Hoppe

Lancet HIV· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Increasing Concentrations of Rifampicin on Different Mycobacterium tuberculosis Lineages in a Whole-Blood Bactericidal Activity Assay.
Rupangi Verma, Meera Gurumurthy, Benjamin Chaik Meng Yeo, Qingshu Lu, Claire M Naftalin, Nicholas I Paton

Antimicrob Agents Chemother· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Doxycycline host-directed therapy in human pulmonary tuberculosis.
Qing Hao Miow, Andres F Vallejo, Yu Wang, Jia Mei Hong, Chen Bai, Nicholas I Paton

J Clin Invest· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.
Nicholas I Paton, Joseph Musaazi, Cissy Kityo, Stephen Walimbwa, Anne Hoppe

N Engl J Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A blood RNA transcriptome signature for COVID-19.
Philip Kam Weng Kwan, Gail B Cross, Claire M Naftalin, Bintou A Ahidjo, Chee Keng Mok, Nicholas I Paton

BMC Med Genomics· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of 68Ga-DOTANOC with 18F-FDG using PET/MRI imaging in patients with pulmonary tuberculosis.
Claire M Naftalin, Francesca Leek, James T P D Hallinan, Lih Kin Khor, John J Totman, Nicholas I Paton

Sci Rep· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perceptions and Acceptability of Digital Interventions Among Tuberculosis Patients in Cambodia: Qualitative Study of Video-Based Directly Observed Therapy.
Lila Rabinovich, James Steven Molton, Wei Tsang Ooi, Nicholas Iain Paton, Shelly Batra

J Med Internet Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A blood RNA transcript signature for TB exposure in household contacts.
Philip Kam Weng Kwan, Balamurugan Periaswamy, Paola Florez De Sessions, Wenwei Lin, James S Molton, Nicholas I Paton

BMC Infect Dis· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis